{
    "abstract": "The development of a group B Streptococcus (GBS)vaccine for maternal immunization constitutes a global public health priority, to prevent GBS-associated early life invasive disease, stillbirth, premature birth, maternal sepsis, adverse neurodevelopmental consequences, and to reduce perinatal antibiotic use. Sample size requirements for the conduct of a randomized placebo-controlled trial to assess vaccine efficacy against the most relevant clinical endpoints, under conditions of appropriate ethical standards of care, constitute a significant obstacle on the pathway to vaccine availability. Alternatively, indirect evidence of protection based on immunologic data from vaccine and sero-epidemiological studies, complemented by data from opsonophagocytic in vitro assays and animal models, could be considered as pivotal data for licensure, with subsequent confirmation of effectiveness against disease outcomes in post-licensure evaluations. Based on discussions initiated by the World Health Organization we present key considerations about the potential role of correlates of protection towards an accelerated pathway for GBS vaccine licensure and wide scale use. Priority activities to support progress to regulatory and policy decision are outlined.",
    "author_highlights": [
        {
            "endOffset": 11381,
            "sentence": "There is a major public health need for GBS vaccines for maternal immunization.",
            "startOffset": 11302
        },
        {
            "endOffset": 11468,
            "sentence": "Important obstacles lie in the way of a pivotal clinical efficacy trial for licensure.",
            "startOffset": 11382
        },
        {
            "endOffset": 11555,
            "sentence": "A vaccine development pathway based on an immune correlate of protection is envisaged.",
            "startOffset": 11469
        },
        {
            "endOffset": 11653,
            "sentence": "Key considerations and priority activities for success are presented, based on WHO consultations.",
            "startOffset": 11556
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Anna C.",
                    "initial": "A.C.",
                    "last": "Seale"
                },
                {
                    "first": "Fiorella",
                    "initial": "F.",
                    "last": "Bianchi-Jassir"
                },
                {
                    "first": "Neal J.",
                    "initial": "N.J.",
                    "last": "Russell"
                },
                {
                    "first": "Maya",
                    "initial": "M.",
                    "last": "Kohli-Lynch"
                },
                {
                    "first": "Cally J.",
                    "initial": "C.J.",
                    "last": "Tann"
                },
                {
                    "first": "Jenny",
                    "initial": "J.",
                    "last": "Hall"
                },
                {
                    "first": "Lola",
                    "initial": "L.",
                    "last": "Madrid"
                },
                {
                    "first": "Hannah",
                    "initial": "H.",
                    "last": "Blencowe"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Cousens"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Bartlett"
                },
                {
                    "first": "Clare",
                    "initial": "C.",
                    "last": "Cutland"
                },
                {
                    "first": "Michael G.",
                    "initial": "M.G.",
                    "last": "Gravett"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Ip"
                },
                {
                    "first": "Kirsty",
                    "initial": "K.",
                    "last": "Le Doare"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Craig E.",
                    "initial": "C.E.",
                    "last": "Rubens"
                },
                {
                    "first": "Samir K.",
                    "initial": "S.K.",
                    "last": "Saha"
                },
                {
                    "first": "Stephanie J.",
                    "initial": "S.J.",
                    "last": "Schrag"
                },
                {
                    "first": "Ajoke",
                    "initial": "A.",
                    "last": "Sobanjo-Ter Meulen"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Vekemans"
                },
                {
                    "first": "Joy E.",
                    "initial": "J.E.",
                    "last": "Lawn"
                }
            ],
            "doi": "10.1093/cid/cix664",
            "firstpage": "S200",
            "issn": "10584838",
            "lastpage": "S219",
            "pmid": "29117332",
            "pub_year": 2017,
            "title": "Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children",
            "volume": "65"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Neal J.",
                    "initial": "N.J.",
                    "last": "Russell"
                },
                {
                    "first": "Anna C.",
                    "initial": "A.C.",
                    "last": "Seale"
                },
                {
                    "first": "Megan",
                    "initial": "M.",
                    "last": "O'Driscoll"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "O'Sullivan"
                },
                {
                    "first": "Fiorella",
                    "initial": "F.",
                    "last": "Bianchi-Jassir"
                },
                {
                    "first": "Juan",
                    "initial": "J.",
                    "last": "Gonzalez-Guarin"
                },
                {
                    "first": "Joy E.",
                    "initial": "J.E.",
                    "last": "Lawn"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Bartlett"
                },
                {
                    "first": "Clare",
                    "initial": "C.",
                    "last": "Cutland"
                },
                {
                    "first": "Michael G.",
                    "initial": "M.G.",
                    "last": "Gravett"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "Kirsty",
                    "initial": "K.",
                    "last": "Le Doare"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Craig E.",
                    "initial": "C.E.",
                    "last": "Rubens"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Schrag"
                },
                {
                    "first": "Ajoke",
                    "initial": "A.",
                    "last": "Sobanjo-Ter Meulen"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Vekemans"
                },
                {
                    "first": "Samir K.",
                    "initial": "S.K.",
                    "last": "Saha"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Ip"
                }
            ],
            "doi": "10.1093/cid/cix658",
            "firstpage": "S100",
            "issn": "10584838",
            "lastpage": "S111",
            "pmid": "29117327",
            "pub_year": 2017,
            "title": "Maternal Colonization with Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses",
            "volume": "65"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Vekemans"
                },
                {
                    "first": "Vasee",
                    "initial": "V.",
                    "last": "Moorthy"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Friede"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Alderson"
                },
                {
                    "first": "Ajoke",
                    "initial": "A.",
                    "last": "Sobanjo-Ter Meulen"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Kirsty",
                    "initial": "K.",
                    "last": "Mehring-Le Doare"
                },
                {
                    "first": "Samir K.",
                    "initial": "S.K.",
                    "last": "Saha"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Schrag"
                },
                {
                    "first": "David C.",
                    "initial": "D.C.",
                    "last": "Kaslow"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.09.087",
            "firstpage": "7391",
            "issn": "0264410X",
            "lastpage": "7393",
            "pmid": "29398277",
            "pub_year": 2019,
            "title": "Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics",
            "volume": "37"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Lola",
                    "initial": "L.",
                    "last": "Madrid"
                },
                {
                    "first": "Anna C.",
                    "initial": "A.C.",
                    "last": "Seale"
                },
                {
                    "first": "Maya",
                    "initial": "M.",
                    "last": "Kohli-Lynch"
                },
                {
                    "first": "Karen M.",
                    "initial": "K.M.",
                    "last": "Edmond"
                },
                {
                    "first": "Joy E.",
                    "initial": "J.E.",
                    "last": "Lawn"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Bartlett"
                },
                {
                    "first": "Clare",
                    "initial": "C.",
                    "last": "Cutland"
                },
                {
                    "first": "Michael G.",
                    "initial": "M.G.",
                    "last": "Gravett"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Ip"
                },
                {
                    "first": "Kirsty",
                    "initial": "K.",
                    "last": "Le Doare"
                },
                {
                    "first": "Craig E.",
                    "initial": "C.E.",
                    "last": "Rubens"
                },
                {
                    "first": "Samir K.",
                    "initial": "S.K.",
                    "last": "Saha"
                },
                {
                    "first": "Ajoke",
                    "initial": "A.",
                    "last": "Sobanjo-Ter Meulen"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Vekemans"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Schrag"
                }
            ],
            "doi": "10.1093/cid/cix656",
            "firstpage": "S160",
            "issn": "10584838",
            "lastpage": "S172",
            "pmid": "29117326",
            "pub_year": 2017,
            "title": "Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses",
            "volume": "65"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Clare L.",
                    "initial": "C.L.",
                    "last": "Cutland"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Jose"
                },
                {
                    "first": "Anthonet",
                    "initial": "A.",
                    "last": "Koen"
                },
                {
                    "first": "Niresha",
                    "initial": "N.",
                    "last": "Govender"
                },
                {
                    "first": "Frederick",
                    "initial": "F.",
                    "last": "Wittke"
                },
                {
                    "first": "Morounfolu",
                    "initial": "M.",
                    "last": "Olugbosi"
                },
                {
                    "first": "Ajoke Sobanjo ter",
                    "initial": "A.S.t.",
                    "last": "Meulen"
                },
                {
                    "first": "Sherryl",
                    "initial": "S.",
                    "last": "Baker"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Vas",
                    "initial": "V.",
                    "last": "Narasimhan"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Slobod"
                }
            ],
            "doi": "10.1016/S1473-3099(16)00152-3",
            "firstpage": "923",
            "issn": "14733099",
            "lastpage": "934",
            "pmid": "27139805",
            "pub_year": 2016,
            "title": "Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial",
            "volume": "16"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Fabbrini"
                },
                {
                    "first": "Fabio",
                    "initial": "F.",
                    "last": "Rigat"
                },
                {
                    "first": "Giovanna",
                    "initial": "G.",
                    "last": "Tuscano"
                },
                {
                    "first": "Emiliano",
                    "initial": "E.",
                    "last": "Chiarot"
                },
                {
                    "first": "Gilbert",
                    "initial": "G.",
                    "last": "Donders"
                },
                {
                    "first": "Roland",
                    "initial": "R.",
                    "last": "Devlieger"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Filippini"
                },
                {
                    "first": "Elisabetta",
                    "initial": "E.",
                    "last": "Frigimelica"
                },
                {
                    "first": "Pietro",
                    "initial": "P.",
                    "last": "Forte"
                },
                {
                    "first": "Frederick",
                    "initial": "F.",
                    "last": "Wittke"
                },
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Slobod"
                },
                {
                    "first": "Guido",
                    "initial": "G.",
                    "last": "Grandi"
                },
                {
                    "first": "Immaculada",
                    "initial": "I.",
                    "last": "Margarit"
                }
            ],
            "doi": "10.1016/j.jinf.2018.01.006",
            "firstpage": "449",
            "issn": "01634453",
            "lastpage": "456",
            "pmid": "29374589",
            "pub_year": 2018,
            "title": "Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women",
            "volume": "76"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Heyderman"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Neil",
                    "initial": "N.",
                    "last": "French"
                },
                {
                    "first": "Clare",
                    "initial": "C.",
                    "last": "Cutland"
                },
                {
                    "first": "Bagrey",
                    "initial": "B.",
                    "last": "Ngwira"
                },
                {
                    "first": "Doris",
                    "initial": "D.",
                    "last": "Kayambo"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Mboizi"
                },
                {
                    "first": "Anthonet",
                    "initial": "A.",
                    "last": "Koen"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Jose"
                },
                {
                    "first": "Morounfolu",
                    "initial": "M.",
                    "last": "Olugbosi"
                },
                {
                    "first": "Frederik",
                    "initial": "F.",
                    "last": "Wittke"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Slobod"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/S1473-3099(15)00484-3",
            "firstpage": "546",
            "issn": "14733099",
            "lastpage": "555",
            "pmid": "26869376",
            "pub_year": 2016,
            "title": "Group B streptococcus vaccination in pregnant women with or without HIV in Africa: A non-randomised phase 2, open-label, multicentre trial",
            "volume": "16"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Anthonet",
                    "initial": "A.",
                    "last": "Koen"
                },
                {
                    "first": "Clare L.",
                    "initial": "C.L.",
                    "last": "Cutland"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Jose"
                },
                {
                    "first": "Niresha",
                    "initial": "N.",
                    "last": "Govender"
                },
                {
                    "first": "Frederick",
                    "initial": "F.",
                    "last": "Wittke"
                },
                {
                    "first": "Morounfolu",
                    "initial": "M.",
                    "last": "Olugbosi"
                },
                {
                    "first": "Ajoke",
                    "initial": "A.",
                    "last": "Sobanjo-Ter Meulen"
                },
                {
                    "first": "Sherryl",
                    "initial": "S.",
                    "last": "Baker"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Vas",
                    "initial": "V.",
                    "last": "Narasimhan"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Slobod"
                }
            ],
            "doi": "10.1093/cid/cix666",
            "firstpage": "1897",
            "issn": "10584838",
            "lastpage": "1904",
            "pmid": "29029127",
            "pub_year": 2017,
            "title": "Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197 -Conjugate Vaccine during Pregnancy",
            "volume": "65"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Ziyaad",
                    "initial": "Z.",
                    "last": "Dangor"
                },
                {
                    "first": "Sanjay G.",
                    "initial": "S.G.",
                    "last": "Lala"
                },
                {
                    "first": "Gaurav",
                    "initial": "G.",
                    "last": "Kwatra"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                }
            ],
            "doi": "10.1097/QCO.0000000000000266",
            "firstpage": "262",
            "issn": "09517375",
            "lastpage": "267",
            "pmid": "26926474",
            "pub_year": 2016,
            "title": "Group B Streptococcus: Developing a correlate of protection for a vaccine against neonatal infections",
            "volume": "29"
        },
        "b0050": null,
        "b0055": {
            "authors": [
                {
                    "first": "Conor P.",
                    "initial": "C.P.",
                    "last": "Farrington"
                },
                {
                    "first": "Godfrey",
                    "initial": "G.",
                    "last": "Manning"
                }
            ],
            "doi": "10.1002/sim.4780091208",
            "firstpage": "1447",
            "issn": "02776715",
            "lastpage": "1454",
            "pmid": "2281232",
            "pub_year": 1990,
            "title": "Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non\u2010zero risk difference or non\u2010unity relative risk",
            "volume": "9"
        },
        "b0060": null,
        "b0065": null,
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "Stanley A.",
                    "initial": "S.A.",
                    "last": "Plotkin"
                }
            ],
            "doi": "10.1086/589862",
            "firstpage": "401",
            "issn": "10584838",
            "lastpage": "409",
            "pmid": "18558875",
            "pub_year": 2008,
            "title": "Correlates of vaccine-induced immunity",
            "volume": "47"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Stanley A.",
                    "initial": "S.A.",
                    "last": "Plotkin"
                }
            ],
            "doi": "10.1128/CVI.00131-10",
            "firstpage": "1055",
            "issn": "15566811",
            "lastpage": "1065",
            "pmid": "20463105",
            "pub_year": 2010,
            "title": "Correlates of protection induced by vaccination",
            "volume": "17"
        },
        "b0085": null,
        "b0090": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Kayhty"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Peltola"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Karanko"
                },
                {
                    "first": "P. H.",
                    "initial": "P.H.",
                    "last": "Makela"
                }
            ],
            "doi": "10.1093/infdis/147.6.1100",
            "firstpage": "1100",
            "issn": "00221899",
            "pmid": "6602191",
            "pub_year": 1983,
            "title": "The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b",
            "volume": "147"
        },
        "b0095": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                }
            ],
            "doi": "10.1006/biol.1994.1062",
            "firstpage": "397",
            "issn": "10451056",
            "lastpage": "402",
            "pub_year": 1994,
            "title": "Difficulties in establishing a serological correlate of protection after immunization with haemophilus influenzae conjugate vaccines",
            "volume": "22"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Josefina",
                    "initial": "J.",
                    "last": "Fernandez"
                },
                {
                    "first": "Orin S.",
                    "initial": "O.S.",
                    "last": "Levine"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Sanchez"
                },
                {
                    "first": "Sharon",
                    "initial": "S.",
                    "last": "Balter"
                },
                {
                    "first": "Leslye",
                    "initial": "L.",
                    "last": "LaClaire"
                },
                {
                    "first": "Jesus",
                    "initial": "J.",
                    "last": "Feris"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Romero-Steiner"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Gomez"
                },
                {
                    "first": "Zacarias",
                    "initial": "Z.",
                    "last": "Garib"
                },
                {
                    "first": "Pedro Luis",
                    "initial": "P.L.",
                    "last": "Castellanos"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Wohl"
                },
                {
                    "first": "Christel",
                    "initial": "C.",
                    "last": "Biltoft"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Zell"
                }
            ],
            "doi": "10.1086/315870",
            "firstpage": "1553",
            "issn": "00221899",
            "lastpage": "1556",
            "pmid": "11023481",
            "pub_year": 2000,
            "title": "Prevention of Haemophilus influenzae type b colonization by vaccination: Correlation with serum anti-capsular IgG concentration",
            "volume": "182"
        },
        "b0105": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1307",
            "firstpage": "1307",
            "issn": "00221007",
            "lastpage": "1326",
            "pmid": "4977280",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. I. The role of humoral antibodies.",
            "volume": "129"
        },
        "b0110": {
            "authors": [
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Salisbury"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ramsay"
                }
            ],
            "doi": "10.1016/S0264-410X(01)00299-7",
            "firstpage": "S58",
            "issn": "0264410X",
            "lastpage": "S67",
            "pmid": "11587814",
            "pub_year": 2001,
            "title": "Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story",
            "volume": "20"
        },
        "b0115": {
            "authors": [
                {
                    "first": "D. M.",
                    "initial": "D.M.",
                    "last": "Daugla"
                },
                {
                    "first": "J. P.",
                    "initial": "J.P.",
                    "last": "Gami"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Gamougam"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Naibei"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Mbainadji"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Narb\u00e9"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Toralta"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Kodbesse"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Ngadoua"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Coldiron"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Page"
                },
                {
                    "first": "M. H.",
                    "initial": "M.H.",
                    "last": "Djingarey"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Hugonnet"
                },
                {
                    "first": "O. B.",
                    "initial": "O.B.",
                    "last": "Harrison"
                },
                {
                    "first": "L. S.",
                    "initial": "L.S.",
                    "last": "Rebbetts"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Tekletsion"
                },
                {
                    "first": "E. R.",
                    "initial": "E.R.",
                    "last": "Watkins"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Hill"
                },
                {
                    "first": "D. A.",
                    "initial": "D.A.",
                    "last": "Caugant"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Chandramohan"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Hassan-King"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Manigart"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Nascimento"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Woukeu"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Trotter"
                },
                {
                    "first": "J. M.",
                    "initial": "J.M.",
                    "last": "Stuart"
                },
                {
                    "first": "M. C.J.",
                    "initial": "M.C.J.",
                    "last": "Maiden"
                },
                {
                    "first": "B. M.",
                    "initial": "B.M.",
                    "last": "Greenwood"
                }
            ],
            "doi": "10.1016/S0140-6736(13)61612-8",
            "firstpage": "40",
            "issn": "01406736",
            "lastpage": "47",
            "pmid": "24035220",
            "pub_year": 2014,
            "title": "Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: A community study",
            "volume": "383"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Jordan W.",
                    "initial": "J.W.",
                    "last": "Tappero"
                },
                {
                    "first": "Rosanna",
                    "initial": "R.",
                    "last": "Lagos"
                },
                {
                    "first": "Aurora Maldonado",
                    "initial": "A.M.",
                    "last": "Ballesteros"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Plikaytis"
                },
                {
                    "first": "Derrick",
                    "initial": "D.",
                    "last": "Williams"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Dykes"
                },
                {
                    "first": "Linda L.",
                    "initial": "L.L.",
                    "last": "Gheesling"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                },
                {
                    "first": "E. Arne",
                    "initial": "E.A.",
                    "last": "H\u00f8iby"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Holst"
                },
                {
                    "first": "Hanne",
                    "initial": "H.",
                    "last": "N\u00f8kleby"
                },
                {
                    "first": "Einar",
                    "initial": "E.",
                    "last": "Rosenqvist"
                },
                {
                    "first": "Gustavo",
                    "initial": "G.",
                    "last": "Sierra"
                },
                {
                    "first": "Concepci\u00f3n",
                    "initial": "C.",
                    "last": "Campa"
                },
                {
                    "first": "Franklin",
                    "initial": "F.",
                    "last": "Sotolongo"
                },
                {
                    "first": "Jeanette",
                    "initial": "J.",
                    "last": "Vega"
                },
                {
                    "first": "Julio",
                    "initial": "J.",
                    "last": "Garcia"
                },
                {
                    "first": "Patricio",
                    "initial": "P.",
                    "last": "Herrera"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Bradley A.",
                    "initial": "B.A.",
                    "last": "Perkins"
                }
            ],
            "doi": "10.1001/jama.281.16.1520",
            "firstpage": "1520",
            "issn": "00987484",
            "lastpage": "1527",
            "pmid": "10227322",
            "pub_year": 1999,
            "title": "Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile",
            "volume": "281"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Lorry",
                    "initial": "L.",
                    "last": "Rubin"
                },
                {
                    "first": "Temitope",
                    "initial": "T.",
                    "last": "Folaranmi"
                },
                {
                    "first": "Ismael R.",
                    "initial": "I.R.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Manisha",
                    "initial": "M.",
                    "last": "Patel"
                },
                {
                    "first": "Stacey W.",
                    "initial": "S.W.",
                    "last": "Martin"
                }
            ],
            "doi": "10.15585/mmwr.mm6441a3",
            "firstpage": "1171",
            "issn": "01492195",
            "lastpage": "1176",
            "pmid": "26492381",
            "pub_year": 2015,
            "title": "Use of serogroup B meningococcal vaccines in adolescents and young adults: Recommendations of the advisory committee on immunization practices, 2015",
            "volume": "64"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Sydel R.",
                    "initial": "S.R.",
                    "last": "Parikh"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Andrews"
                },
                {
                    "first": "Kazim",
                    "initial": "K.",
                    "last": "Beebeejaun"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Charlotte",
                    "initial": "C.",
                    "last": "Ward"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "White"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                }
            ],
            "doi": "10.1016/S0140-6736(16)31921-3",
            "firstpage": "2775",
            "issn": "01406736",
            "lastpage": "2782",
            "pmid": "28100432",
            "pub_year": 2016,
            "title": "Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study",
            "volume": "388"
        },
        "b0135": {
            "authors": [
                {
                    "first": "George R.",
                    "initial": "G.R.",
                    "last": "Siber"
                },
                {
                    "first": "Ih",
                    "initial": "I.",
                    "last": "Chang"
                },
                {
                    "first": "Sherryl",
                    "initial": "S.",
                    "last": "Baker"
                },
                {
                    "first": "Philip",
                    "initial": "P.",
                    "last": "Fernsten"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Mathuram",
                    "initial": "M.",
                    "last": "Santosham"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Paradiso"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Kohberger"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.01.119",
            "firstpage": "3816",
            "issn": "0264410X",
            "lastpage": "3826",
            "pmid": "17368878",
            "pub_year": 2007,
            "title": "Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies",
            "volume": "25"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Andrews"
                },
                {
                    "first": "Pauline A.",
                    "initial": "P.A.",
                    "last": "Waight"
                },
                {
                    "first": "Polly",
                    "initial": "P.",
                    "last": "Burbidge"
                },
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Pearce"
                },
                {
                    "first": "Lucy",
                    "initial": "L.",
                    "last": "Roalfe"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Zancolli"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Slack"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Goldblatt"
                }
            ],
            "doi": "10.1016/S1473-3099(14)70822-9",
            "firstpage": "839",
            "issn": "14733099",
            "lastpage": "846",
            "pmid": "25042756",
            "pub_year": 2014,
            "title": "Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: A postlicensure indirect cohort study",
            "volume": "14"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Jukka T.",
                    "initial": "J.T.",
                    "last": "Jokinen"
                },
                {
                    "first": "Heidi",
                    "initial": "H.",
                    "last": "\u00c5hman"
                },
                {
                    "first": "Terhi M.",
                    "initial": "T.M.",
                    "last": "Kilpi"
                },
                {
                    "first": "P. Helena",
                    "initial": "P.H.",
                    "last": "M\u00e4kel\u00e4"
                },
                {
                    "first": "M. Helena",
                    "initial": "M.H.",
                    "last": "K\u00e4yhty"
                }
            ],
            "doi": "10.1086/422531",
            "firstpage": "545",
            "issn": "00221899",
            "lastpage": "550",
            "pmid": "15243930",
            "pub_year": 2004,
            "title": "Concentration of antipneumococcal antibodies as a serological correlate of protection: An application to acute otitis media",
            "volume": "190"
        },
        "b0150": {
            "authors": [
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Ojal"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Goldblatt"
                },
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Tigoi"
                },
                {
                    "first": "J. Anthony G.",
                    "initial": "J.A.G.",
                    "last": "Scott"
                }
            ],
            "doi": "10.1093/cid/cix742",
            "firstpage": "121",
            "issn": "10584838",
            "lastpage": "130",
            "pmid": "29020230",
            "pub_year": 2018,
            "title": "Effect of Maternally Derived Anti-protein and Anticapsular IgG Antibodies on the Rate of Acquisition of Nasopharyngeal Carriage of Pneumococcus in Newborns",
            "volume": "66"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "doi": "10.1056/NEJM197604012941404",
            "firstpage": "753",
            "issn": "00284793",
            "lastpage": "756",
            "pmid": "768760",
            "pub_year": 1976,
            "title": "Correlation of Maternal Antibody Deficiency with Susceptibility to Neonatal Group B Streptococcal Infection",
            "volume": "294"
        },
        "b0160": {
            "authors": [
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "D. L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "firstpage": "544",
            "issn": "00314005",
            "lastpage": "549",
            "pmid": "7033911",
            "pub_year": 1981,
            "title": "Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection",
            "volume": "68"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Feng Ying",
                    "initial": "F.Y.",
                    "last": "Lin"
                },
                {
                    "first": "Joseph B.",
                    "initial": "J.B.",
                    "last": "Philips"
                },
                {
                    "first": "Parvin H.",
                    "initial": "P.H.",
                    "last": "Azimi"
                },
                {
                    "first": "Leonard E.",
                    "initial": "L.E.",
                    "last": "Weisman"
                },
                {
                    "first": "Penny",
                    "initial": "P.",
                    "last": "Clark"
                },
                {
                    "first": "George G.",
                    "initial": "G.G.",
                    "last": "Rhoads"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Regan"
                },
                {
                    "first": "Nelydia F.",
                    "initial": "N.F.",
                    "last": "Concepcion"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Troendle"
                },
                {
                    "first": "Ruth A.",
                    "initial": "R.A.",
                    "last": "Brenner"
                },
                {
                    "first": "Barry M.",
                    "initial": "B.M.",
                    "last": "Gray"
                },
                {
                    "first": "Reva",
                    "initial": "R.",
                    "last": "Bhushan"
                },
                {
                    "first": "Geri",
                    "initial": "G.",
                    "last": "Fitzgerald"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Moyer"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1086/323350",
            "firstpage": "1022",
            "issn": "00221899",
            "lastpage": "1028",
            "pmid": "11574917",
            "pub_year": 2001,
            "title": "Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: A multicenter, seroepidemiology study",
            "volume": "184"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Feng Ying C.",
                    "initial": "F.Y.C.",
                    "last": "Lin"
                },
                {
                    "first": "Leonard E.",
                    "initial": "L.E.",
                    "last": "Weisman"
                },
                {
                    "first": "Parvin H.",
                    "initial": "P.H.",
                    "last": "Azimi"
                },
                {
                    "first": "Joseph B.",
                    "initial": "J.B.",
                    "last": "Philips"
                },
                {
                    "first": "Penny",
                    "initial": "P.",
                    "last": "Clark"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Regan"
                },
                {
                    "first": "George G.",
                    "initial": "G.G.",
                    "last": "Rhoads"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Barry M.",
                    "initial": "B.M.",
                    "last": "Gray"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Troendle"
                },
                {
                    "first": "Ruth A.",
                    "initial": "R.A.",
                    "last": "Brenner"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Moyer"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1086/422756",
            "firstpage": "928",
            "issn": "00221899",
            "lastpage": "934",
            "pmid": "15295698",
            "pub_year": 2004,
            "title": "Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen",
            "volume": "190"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Carol J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "Vincent J.",
                    "initial": "V.J.",
                    "last": "Carey"
                },
                {
                    "first": "Marcia A.",
                    "initial": "M.A.",
                    "last": "Rench"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Sharon L.",
                    "initial": "S.L.",
                    "last": "Hillier"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Platt"
                }
            ],
            "doi": "10.1093/infdis/jit549",
            "firstpage": "781",
            "issn": "00221899",
            "lastpage": "788",
            "pmid": "24133184",
            "pub_year": 2014,
            "title": "Maternal antibody at delivery protects neonates from early onset group B streptococcal disease",
            "volume": "209"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Ziyaad",
                    "initial": "Z.",
                    "last": "Dangor"
                },
                {
                    "first": "Gaurav",
                    "initial": "G.",
                    "last": "Kwatra"
                },
                {
                    "first": "Alane",
                    "initial": "A.",
                    "last": "Izu"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Adrian"
                },
                {
                    "first": "Clare L.",
                    "initial": "C.L.",
                    "last": "Cutland"
                },
                {
                    "first": "Sithembiso",
                    "initial": "S.",
                    "last": "Velaphi"
                },
                {
                    "first": "Daynia",
                    "initial": "D.",
                    "last": "Ballot"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Reubenson"
                },
                {
                    "first": "Elizabeth R.",
                    "initial": "E.R.",
                    "last": "Zell"
                },
                {
                    "first": "Sanjay G.",
                    "initial": "S.G.",
                    "last": "Lala"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.10.019",
            "firstpage": "6793",
            "issn": "0264410X",
            "lastpage": "6799",
            "pmid": "26478200",
            "pub_year": 2015,
            "title": "Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants",
            "volume": "33"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Fabbrini"
                },
                {
                    "first": "Fabio",
                    "initial": "F.",
                    "last": "Rigat"
                },
                {
                    "first": "C. Daniela",
                    "initial": "C.D.",
                    "last": "Rinaudo"
                },
                {
                    "first": "Irene",
                    "initial": "I.",
                    "last": "Passalaqua"
                },
                {
                    "first": "Sceida",
                    "initial": "S.",
                    "last": "Khacheh"
                },
                {
                    "first": "Roberta",
                    "initial": "R.",
                    "last": "Creti"
                },
                {
                    "first": "Lucilla",
                    "initial": "L.",
                    "last": "Baldassarri"
                },
                {
                    "first": "Filippo",
                    "initial": "F.",
                    "last": "Carboni"
                },
                {
                    "first": "Giulia",
                    "initial": "G.",
                    "last": "Anderloni"
                },
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Rosini"
                },
                {
                    "first": "Domenico",
                    "initial": "D.",
                    "last": "Maione"
                },
                {
                    "first": "Guido",
                    "initial": "G.",
                    "last": "Grandi"
                },
                {
                    "first": "John L.",
                    "initial": "J.L.",
                    "last": "Telford"
                },
                {
                    "first": "Immaculada",
                    "initial": "I.",
                    "last": "Margarit"
                }
            ],
            "doi": "10.1093/cid/ciw377",
            "firstpage": "746",
            "issn": "10584838",
            "lastpage": "753",
            "pmid": "27402816",
            "pub_year": 2016,
            "title": "The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera",
            "volume": "63"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Kirsty",
                    "initial": "K.",
                    "last": "Le Doare"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Kampmann"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Vekemans"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Goldblatt"
                },
                {
                    "first": "Moon H.",
                    "initial": "M.H.",
                    "last": "Nahm"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Baker"
                },
                {
                    "first": "Morven S.",
                    "initial": "M.S.",
                    "last": "Edwards"
                },
                {
                    "first": "Gaurav",
                    "initial": "G.",
                    "last": "Kwatra"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Ajoke Sobanjo",
                    "initial": "A.S.",
                    "last": "ter Meulen"
                },
                {
                    "first": "Annaliesa S.",
                    "initial": "A.S.",
                    "last": "Anderson"
                },
                {
                    "first": "Bart",
                    "initial": "B.",
                    "last": "Corsaro"
                },
                {
                    "first": "Per",
                    "initial": "P.",
                    "last": "Fischer"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Gorringe"
                }
            ],
            "doi": "10.1016/S1473-3099(18)30659-5",
            "firstpage": "e162",
            "issn": "14733099",
            "lastpage": "e171",
            "pmid": "30683467",
            "pub_year": 2019,
            "title": "Serocorrelates of protection against infant group B streptococcus disease",
            "volume": "19"
        },
        "b0195": {
            "authors": [
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Larsson"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Lindroth"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Nordin"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "St\u00e5lhammar-Carlemalm"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Lindahl"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Krantz"
                }
            ],
            "doi": "10.1136/adc.2005.090472",
            "firstpage": "F403",
            "issn": "13592998",
            "lastpage": "F408",
            "pmid": "17056838",
            "pub_year": 2006,
            "title": "Association between low concentrations of antibodies to protein \u03b1 and Rib and invasive neonatal group B streptococcal infection",
            "volume": "91"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Ziyaad",
                    "initial": "Z.",
                    "last": "Dangor"
                },
                {
                    "first": "Gaurav",
                    "initial": "G.",
                    "last": "Kwatra"
                },
                {
                    "first": "Alane",
                    "initial": "A.",
                    "last": "Izu"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Adrian"
                },
                {
                    "first": "Clare L.",
                    "initial": "C.L.",
                    "last": "Cutland"
                },
                {
                    "first": "Sithembiso",
                    "initial": "S.",
                    "last": "Velaphi"
                },
                {
                    "first": "Daynia",
                    "initial": "D.",
                    "last": "Ballot"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Reubenson"
                },
                {
                    "first": "Elizabeth R.",
                    "initial": "E.R.",
                    "last": "Zell"
                },
                {
                    "first": "Sanjay G.",
                    "initial": "S.G.",
                    "last": "Lala"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                }
            ],
            "doi": "10.1586/14760584.2015.1085307",
            "firstpage": "1651",
            "issn": "14760584",
            "lastpage": "1660",
            "pmid": "26364978",
            "pub_year": 2015,
            "title": "Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants",
            "volume": "14"
        },
        "b0205": {
            "authors": [
                {
                    "first": "R. S.",
                    "initial": "R.S.",
                    "last": "Baltimore"
                },
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Baker"
                },
                {
                    "first": "D. L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "doi": "10.1128/iai.32.1.56-61.1981",
            "firstpage": "56",
            "issn": "00199567",
            "lastpage": "61",
            "pmid": "7216494",
            "pub_year": 1981,
            "title": "Antibody to group B Streptococcus type III in human sera measured by a mouse protection test",
            "volume": "32"
        },
        "b0210": {
            "authors": [
                {
                    "first": "Val G.",
                    "initial": "V.G.",
                    "last": "Hemming"
                },
                {
                    "first": "William T.",
                    "initial": "W.T.",
                    "last": "London"
                },
                {
                    "first": "Gerald W.",
                    "initial": "G.W.",
                    "last": "Fischer"
                },
                {
                    "first": "Blanche L.",
                    "initial": "B.L.",
                    "last": "Curfman"
                },
                {
                    "first": "Patricia A.",
                    "initial": "P.A.",
                    "last": "Baron"
                },
                {
                    "first": "Harald",
                    "initial": "H.",
                    "last": "Gloser"
                },
                {
                    "first": "Helmut",
                    "initial": "H.",
                    "last": "Bachmayer"
                },
                {
                    "first": "Samuel R.",
                    "initial": "S.R.",
                    "last": "Wilson"
                }
            ],
            "doi": "10.1093/infdis/156.4.655",
            "firstpage": "655",
            "issn": "00221899",
            "lastpage": "658",
            "pmid": "3305721",
            "pub_year": 1987,
            "title": "Immunoprophylaxis of Postnatally Acquired Group B Streptococcal Sepsis in Neonatal Rhesus Monkeys",
            "volume": "156"
        },
        "b0215": {
            "authors": [
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Madoff"
                },
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Paoletti"
                },
                {
                    "first": "Joseph Y.",
                    "initial": "J.Y.",
                    "last": "Tai"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "doi": "10.1172/JCI117319",
            "firstpage": "286",
            "issn": "00219738",
            "lastpage": "292",
            "pmid": "7518832",
            "pub_year": 1994,
            "title": "Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes",
            "volume": "94"
        },
        "b0220": {
            "authors": [
                {
                    "first": "Jill K.",
                    "initial": "J.K.",
                    "last": "Davies"
                },
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Paoletti"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "McDuffie"
                },
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Madoff"
                },
                {
                    "first": "Scott",
                    "initial": "S.",
                    "last": "Lee"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Eskens"
                },
                {
                    "first": "Ronald S.",
                    "initial": "R.S.",
                    "last": "Gibbs"
                }
            ],
            "doi": "10.1016/S0002-9378(99)70305-4",
            "firstpage": "803",
            "issn": "00029378",
            "lastpage": "808",
            "pmid": "10521733",
            "pub_year": 1999,
            "title": "A randomized trial of conjugated group B streptococcal type Ia vaccine in a rabbit model of ascending infection",
            "volume": "181"
        },
        "b0225": {
            "authors": [
                {
                    "first": "Lawrence C.",
                    "initial": "L.C.",
                    "last": "Paoletti"
                },
                {
                    "first": "Julieanne",
                    "initial": "J.",
                    "last": "Pinel"
                },
                {
                    "first": "Ronald C.",
                    "initial": "R.C.",
                    "last": "Kennedy"
                },
                {
                    "first": "Dennis L.",
                    "initial": "D.L.",
                    "last": "Kasper"
                }
            ],
            "doi": "10.1086/315285",
            "firstpage": "653",
            "issn": "00221899",
            "lastpage": "658",
            "pmid": "10669351",
            "pub_year": 2000,
            "title": "Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate",
            "volume": "181"
        },
        "b0230": {
            "authors": [
                {
                    "first": "Ross L.",
                    "initial": "R.L.",
                    "last": "Prentice"
                }
            ],
            "doi": "10.1002/sim.4780080407",
            "firstpage": "431",
            "issn": "02776715",
            "lastpage": "440",
            "pmid": "2727467",
            "pub_year": 1989,
            "title": "Surrogate endpoints in clinical trials: Definition and operational criteria",
            "volume": "8"
        },
        "b0235": null,
        "b0240": null,
        "b0245": null,
        "b0250": {
            "authors": [
                {
                    "first": "Xuan",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Fabrice",
                    "initial": "F.",
                    "last": "Bailleux"
                },
                {
                    "first": "Kamal",
                    "initial": "K.",
                    "last": "Desai"
                },
                {
                    "first": "Li",
                    "initial": "L.",
                    "last": "Qin"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Dunning"
                }
            ],
            "doi": "10.1186/1471-2288-13-29",
            "issn": "14712288",
            "pmid": "23448322",
            "pub_year": 2013,
            "title": "A threshold method for immunological correlates of protection",
            "volume": "13"
        },
        "b0255": {
            "authors": [
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Binka"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Marsh"
                },
                {
                    "first": "Jon S.",
                    "initial": "J.S.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1016/S0140-6736(16)30394-4",
            "firstpage": "1887",
            "issn": "01406736",
            "lastpage": "1889",
            "pmid": "27203633",
            "pub_year": 2016,
            "title": "Mind the gap: Jumping from vaccine licensure to routine use",
            "volume": "387"
        },
        "b0260": {
            "authors": [
                {
                    "first": "Daniel R.",
                    "initial": "D.R.",
                    "last": "Feikin"
                },
                {
                    "first": "J. Anthony G.",
                    "initial": "J.A.G.",
                    "last": "Scott"
                },
                {
                    "first": "Bradford D.",
                    "initial": "B.D.",
                    "last": "Gessner"
                }
            ],
            "doi": "10.1016/S0140-6736(13)61682-7",
            "firstpage": "1762",
            "issn": "01406736",
            "lastpage": "1770",
            "pmid": "24553294",
            "pub_year": 2014,
            "title": "Use of vaccines as probes to define disease burden",
            "volume": "383"
        }
    },
    "body_text": [
        {
            "endOffset": 23495,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Sometimes the efficacy evidence was derived by analogy to a related vaccine rather than generated from the candidate vaccine itself.",
            "startOffset": 23363,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 39396,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0065",
            "sentence": "Briefly, a systematic case detection system should be implemented to support identification of confirmed GBS cases.",
            "startOffset": 39281,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 32097,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "The association between GBS serotype-specific capsular IgG antibody concentrations at birth and odds of invasive GBS disease will be estimated, for serotypes Ia and III separately.",
            "startOffset": 31917,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 26412,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine was licensed in India in 2009, and pre-qualified by WHO in 2010, on safety and immunogenicity (SBA assays) data only.",
            "startOffset": 26219,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 42641,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "Further research is necessary to understand whether neonatal antibody levels measured may be lowered, in the context of invasive infection, by bacterial binding of antibody, and implications for data interpretation.",
            "startOffset": 42426,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 35292,
            "parents": [],
            "secId": "s0055",
            "sentence": "The most important determining factor for the accelerated approval of a GBS vaccine based on a non-clinical endpoint will be how strongly the available package of evidence is graded as reasonably likely to predict clinical benefit.",
            "startOffset": 35061,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 19524,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "It seems unlikely that the baseline incidence of eligible endpoint cases would be much higher than 0.5\u20131 per 1000 live births, for a trial conducted in the context of fully implemented local healthcare guidelines and optimal access to care.",
            "startOffset": 19284,
            "title": "Randomized controlled vaccine clinical efficacy trial: a sample size challenge"
        },
        {
            "endOffset": 14920,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0015": {
                    "endOffset": 14919,
                    "startOffset": 14916
                }
            },
            "secId": "s0010",
            "sentence": "There are considerable challenges to implementing effective IAP-based prevention strategies, especially in resource-limited settings, and there are concerns about unintended consequences of neonatal antibiotic exposure, including its impact on the gut microbiome and in contributing to the generation of antibiotic resistance [3].",
            "startOffset": 14590,
            "title": "Burden"
        },
        {
            "endOffset": 34789,
            "parents": [],
            "secId": "s0055",
            "sentence": "Whatever the approach, strong evidence establishing the validity of substitute endpoint(s) as reliable predictors of clinical benefit will be required to support regulatory and policy decisions.",
            "startOffset": 34595,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 23164,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Thresholds may also vary by pathogen strain/serotype and clinical syndrome.",
            "startOffset": 23089,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 37536,
            "parents": [],
            "secId": "s0055",
            "sentence": "Specificity (a critical criteria, as other trans-placentally transferred protective immune effectors that are not induced by vaccination could lead to an over-estimate of the potential impact of vaccines); 6.",
            "startOffset": 37328,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 24893,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "CPS conjugation with a carrier protein increased immunogenicity and functional activity in vitro, and a lower antibody threshold of protection than for the polysaccharide vaccine.",
            "startOffset": 24714,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 15331,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 15330,
                    "startOffset": 15326
                }
            },
            "secId": "s0015",
            "sentence": "The development of GBS vaccines suitable for immunization during pregnancy has been identified as a priority by the World Health Organization (WHO), and key consensus documents presenting preferences for GBS vaccine product characteristics and a research and development technology roadmap have been developed [10].",
            "startOffset": 15016,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 42425,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "Antibody levels in cord blood provide an opportunity to define, possibly with more specificity and precision, a functional protective antibody threshold \u2013 the level of antibodies that is required to prevent invasive disease in the offspring, upon initial bacterial penetration into the blood stream.",
            "startOffset": 42126,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 31916,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "A case-control study with similar objectives is also planned in the United States by the Centers for Disease Control and Prevention (CDC).",
            "startOffset": 31778,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 50602,
            "parents": [],
            "secId": "s0095",
            "sentence": "For instance, it will be hard to generate evidence about less common serotypes.",
            "startOffset": 50523,
            "title": "Conclusions"
        },
        {
            "endOffset": 30906,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0040",
            "sentence": "In addition, other studies aiming to characterize correlates of protection are currently underway or being planned.",
            "startOffset": 30791,
            "title": "Current evidence base"
        },
        {
            "endOffset": 30616,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0040",
            "sentence": "There were important differences in the design of the various studies, which were conducted across diverse populations and epidemiological settings, with different standards of care, studying different target antigens, using different reference sera and other control reagents, assay methodologies, analytical methods, and length of follow-up.",
            "startOffset": 30273,
            "title": "Current evidence base"
        },
        {
            "endOffset": 33345,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "A further retrospective study from 2014, based on stored DBS samples, is also underway, using serum samples from 150 cases and three times as many controls (Kirsty Le Doare, personal communication).",
            "startOffset": 33147,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 37660,
            "parents": [],
            "secId": "s0055",
            "sentence": "Plausibility (supported by other maternal immunization platforms and by other vaccines targeting encapsulated bacteria); 7.",
            "startOffset": 37537,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 41156,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0070",
            "sentence": "International agreement on standards and methodologies will provide the necessary support for comparison and bridging studies.",
            "startOffset": 41030,
            "title": "Assay quality systems"
        },
        {
            "endOffset": 31143,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "Enrolment was re-initiated in 2019, to include a further 15,000 pairs.",
            "startOffset": 31073,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 18048,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 18047,
                    "startOffset": 18044
                }
            },
            "secId": "s0015",
            "sentence": "The induction of functional activity and protection from protein-based GBS vaccines have been investigated in preclinical infection models, and further sero-epidemiological studies are required to confirm whether immunity targeting these proteins derived from natural exposure is associated with protection against early life invasive disease [9].",
            "startOffset": 17701,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 36102,
            "parents": [],
            "secId": "s0055",
            "sentence": "The fourth criterion is that the conditional disease risk (the association between the surrogate outcome and the disease risk) is the same in vaccinated and unvaccinated individuals.",
            "startOffset": 35920,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 20151,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "Candidate vaccines against other pathogens have been tested in very large pivotal trials before, but specificities related to GBS, including vaccination of women during pregnancy, the extremely rapid progression of GBS sepsis before and soon after birth, follow up requirements for women in late pregnancy, for babies in the first days and weeks of life, the need to investigate stillbirth and fatal cases, the needs for adequate safety oversight and efficacy monitoring requiring invasive sampling (blood and CSF) and bacteriologic analyses would make such a GBS vaccine trial with clinical endpoints lengthy and very costly.",
            "startOffset": 19525,
            "title": "Randomized controlled vaccine clinical efficacy trial: a sample size challenge"
        },
        {
            "endOffset": 27124,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "However, the highly variable nature of the immunodominant vesicular PorA protein limited strain coverage, and genomic advances in the 2000\u2032s supported the development of new protein vaccine candidates.",
            "startOffset": 26923,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 32871,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "All pairs are planned to be followed up to 90 days after birth.",
            "startOffset": 32808,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 29430,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0150": {
                    "endOffset": 29429,
                    "startOffset": 29425
                }
            },
            "secId": "s0030",
            "sentence": "Results from a study of maternal-foetal transfer of antibodies acquired following natural exposure suggested that even higher antibody levels are needed to prevent pneumococcal carriage in infants [30].",
            "startOffset": 29228,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 25239,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 25238,
                    "startOffset": 25234
                }
            },
            "secId": "s0030",
            "sentence": "Prevalent concentrations above 0.15 \u03bcg/mL are considered as protective against Hib bacteraemia and are accepted as such by regulators for licensure of new vaccines or for bridging studies [15].",
            "startOffset": 25046,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 35852,
            "parents": [],
            "secId": "s0055",
            "sentence": "The third criterion is that surrogates affect outcome.",
            "startOffset": 35798,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 43716,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "refoffsets": {
                "b0250": {
                    "endOffset": 43715,
                    "startOffset": 43711
                }
            },
            "secId": "s0080",
            "sentence": "Whether a threshold or continuous model-based approach is favoured should be predefined [50].",
            "startOffset": 43623,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 31225,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "Infants were followed-up by hospital-based surveillance for invasive GBS disease.",
            "startOffset": 31144,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 39753,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0065",
            "sentence": "Case detection systems need to be applied from late pregnancy or at the time of birth, as most cases of EOD occur on the day of birth.",
            "startOffset": 39619,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 49930,
            "parents": [],
            "secId": "s0095",
            "sentence": "Alternative strategies to accelerate licensure of candidate vaccines must be explored, including efforts to define serological correlates of protection as acceptable substitute endpoints, derived from studies of immunity resulting from natural exposure.",
            "startOffset": 49677,
            "title": "Conclusions"
        },
        {
            "endOffset": 44446,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "Statistical models supporting the assessment of the role of multiple variables may contribute to a better characterization of the strength of the assumptions.",
            "startOffset": 44288,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 33838,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "refoffsets": {
                "b0205": {
                    "endOffset": 33837,
                    "startOffset": 33833
                }
            },
            "secId": "s0050",
            "sentence": "Passive transfer of antibodies targeting the polysaccharide envelope has provided serotype-specific protection from experimental GBS challenge [41].",
            "startOffset": 33690,
            "title": "Animal models"
        },
        {
            "endOffset": 17218,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "A Phase I/2 clinical study in the US has been completed in healthy adults (NCT03170609) and a trial in pregnant women in South Africa, co-funded by the Bill and Melinda Gates Foundation (BMGF), isbeing initiated (NCT03765073).",
            "startOffset": 16992,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 15531,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Consensus-building about a preferred clinical development pathway and defining the pivotal data package requirement for licensure, and policy for vaccine use, were highlighted as priority activities.",
            "startOffset": 15332,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 30272,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0040",
            "sentence": "While antibody-mediated risk reduction estimates have been reported from different studies for the most frequent serotypes (Ia, III, V), rigorous estimates of protective thresholds have not been established.",
            "startOffset": 30065,
            "title": "Current evidence base"
        },
        {
            "endOffset": 13970,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "The reservoir for GBS in humans is the gastrointestinal tract, and maternal recto-vaginal colonization can lead to ascending foetal infection, stillbirth and early onset neonatal sepsis.",
            "startOffset": 13784,
            "title": "Burden"
        },
        {
            "endOffset": 50216,
            "parents": [],
            "secId": "s0095",
            "sentence": "Vaccine development sponsors, advised by regulators and policy makers, will need to decide on their preferred vaccine development pathway for licensure and policy decisions, through a careful analysis of risks and opportunities.",
            "startOffset": 49988,
            "title": "Conclusions"
        },
        {
            "endOffset": 27965,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 27964,
                    "startOffset": 27960
                }
            },
            "secId": "s0030",
            "sentence": "Post-licensure evidence of effectiveness soon emerged [26].",
            "startOffset": 27906,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 31378,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "In parallel, infants with invasive disease that were not enrolled into the birth cohort were, and will further be, identified across multiple hospitals.",
            "startOffset": 31226,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 28473,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 28472,
                    "startOffset": 28468
                }
            },
            "secId": "s0030",
            "sentence": "Although there was no evidence demonstrating that protective thresholds were the same for different serotypes, it was considered acceptable to estimate an aggregate threshold through data pooling, serving as target for all serotypes [27].",
            "startOffset": 28235,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 35061,
            "parents": [],
            "secId": "s0055",
            "sentence": "Key considerations in defining and validating a substitute endpoint",
            "startOffset": 34994,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 40810,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0070",
            "sentence": "High quality standards in assay quantification of antibody level and function should apply.",
            "startOffset": 40719,
            "title": "Assay quality systems"
        },
        {
            "endOffset": 37249,
            "parents": [],
            "secId": "s0055",
            "sentence": "Consistency of association (shown through repeat studies in different settings); 4.",
            "startOffset": 37166,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 26922,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 26921,
                    "startOffset": 26917
                }
            },
            "secId": "s0030",
            "sentence": "Vaccine efficacy had been demonstrated in the 1990s for two OMP-based vaccines derived from outer membrane vesicles (OMV), and the association with hSBA responses (h indicative of human complement use) had been shown [24].",
            "startOffset": 26700,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 38852,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "refoffsets": {
                "b0235": {
                    "endOffset": 38851,
                    "startOffset": 38847
                }
            },
            "secId": "s0060",
            "sentence": "Considerations about pregnancy immunization safety characterization are presented elsewhere [47].",
            "startOffset": 38755,
            "title": "Safety"
        },
        {
            "endOffset": 38409,
            "parents": [],
            "secId": "s0055",
            "sentence": "Animal models of vaccine-induced protection would also add to the evidence that the measured antibodies are clinically relevant.",
            "startOffset": 38281,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 27290,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "In 2013, MenB-4C was licensed in Europe, based on demonstrated SBA against a panel of strains matched to the vaccine antigens in the absence of direct efficacy data.",
            "startOffset": 27125,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 51031,
            "parents": [],
            "secId": "s0095",
            "sentence": "From an early stage in vaccine development, regulators and policy makers should work with sponsors on possible vaccine development pathways.",
            "startOffset": 50891,
            "title": "Conclusions"
        },
        {
            "endOffset": 33551,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0050",
            "sentence": "In addition to sero-epidemiological studies, studies in relevant experimental animal models can contribute to establishing evidence of a protective role of antibodies induced by vaccination.",
            "startOffset": 33361,
            "title": "Animal models"
        },
        {
            "endOffset": 36674,
            "parents": [],
            "secId": "s0055",
            "sentence": "This relies on the assumption that functionality of antibodies induced by vaccination and natural exposure are the same (or closely associated).",
            "startOffset": 36530,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 33689,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0050",
            "sentence": "Such models have provided useful mechanistic insights into the pathogenesis and the impact of antibody-mediated responses on GBS disease.",
            "startOffset": 33552,
            "title": "Animal models"
        },
        {
            "endOffset": 41029,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0070",
            "sentence": "Characterization of the performance of the assay need to be adapted to the vaccine development status, noting that an immunological substitute endpoint should ultimately be based on fully analytically validated assays.",
            "startOffset": 40811,
            "title": "Assay quality systems"
        },
        {
            "endOffset": 38754,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0060",
            "sentence": "When considering risk-benefit, the uncertainty about the benefit derived using a substitute endpoint for licensure might justify setting a higher safety profile expectation.",
            "startOffset": 38581,
            "title": "Safety"
        },
        {
            "endOffset": 41518,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "Samples from both the mother and the offspring should be analysed.",
            "startOffset": 41452,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 43988,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "Statistical evaluations should also be undertaken in consideration of other variables that may impact the validity of the assumptions.",
            "startOffset": 43854,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 48650,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0090",
            "sentence": "Such studies may include cluster-randomised trials, stepped-wedge designs for vaccine introduction, case-control studies or ecological studies monitoring changes in population disease burden.",
            "startOffset": 48459,
            "title": "Post licensure requirements"
        },
        {
            "endOffset": 46827,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0085",
            "sentence": "It is unlikely that reliable vaccine efficacy estimates would be produced for less common serotypes.",
            "startOffset": 46727,
            "title": "Rare serotypes"
        },
        {
            "endOffset": 26550,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 26549,
                    "startOffset": 26545
                }
            },
            "secId": "s0030",
            "sentence": "The vaccine was then deployed in the sub-Saharan Africa meningitis belt and shown to be protective against meningococcal meningitis [23].",
            "startOffset": 26413,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 30064,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0040",
            "sentence": "In most studies, ligand-binding or Luminex\u00ae assays were used; in some, opsonophagocytic in vitro killing assays were used.",
            "startOffset": 29942,
            "title": "Current evidence base"
        },
        {
            "endOffset": 27376,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "In 2015, MenB-4C was introduced in the routine infant vaccination schedule in the UK.",
            "startOffset": 27291,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 47245,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0085",
            "sentence": "As has been done for other multivalent vaccines, an aggregate threshold may need to be derived, based on a weighted average, observations about threshold differences across common serotypes and some plausible assumptions.",
            "startOffset": 47024,
            "title": "Rare serotypes"
        },
        {
            "endOffset": 16848,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 16847,
                    "startOffset": 16844
                }
            },
            "secId": "s0015",
            "sentence": "Vaccination in pregnancy was shown not to inhibit offspring responses to recommended vaccines comprised of CRM197-based conjugates [8].",
            "startOffset": 16713,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 46401,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "For instance, confidence in the extrapolation of immunity from natural exposure to immunity resulting from vaccination can be increased by in-vitro demonstration that the measured antibody is functional, through measurement of bacterial killing assays, and by animal models of protection.",
            "startOffset": 46113,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 13526,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "While data gaps hinder precise estimates for other disease syndromes, a conservative assessment suggests that yearly, 57,000 stillbirths are caused by GBS and 33,000 pregnant or puerperal women have GBS sepsis.",
            "startOffset": 13316,
            "title": "Burden"
        },
        {
            "endOffset": 20731,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "The aim of this report is to highlight the potential role that immune correlates of protection may have for an accelerated GBS vaccine development pathway to licensure and policy decision.",
            "startOffset": 20543,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 29710,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "refoffsets": {
                "b0155": {
                    "endOffset": 29709,
                    "startOffset": 29705
                }
            },
            "secId": "s0040",
            "sentence": "The first suggestion that it may be possible to establish a serological correlate of protection for GBS was presented four decades ago [31].",
            "startOffset": 29570,
            "title": "Current evidence base"
        },
        {
            "endOffset": 50522,
            "parents": [],
            "secId": "s0095",
            "sentence": "Any evaluative approach is likely to include important assumptions and gaps.",
            "startOffset": 50446,
            "title": "Conclusions"
        },
        {
            "endOffset": 16563,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 16562,
                    "startOffset": 16559
                }
            },
            "secId": "s0015",
            "sentence": "Opsonophagocytic bacterial killing activity in umbilical cord sera, correlating with serotype-specific IgG antibody concentrations, and functional activity in a mouse bacterial challenge model, were demonstrated [6].",
            "startOffset": 16347,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 18235,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Another Phase 1 trial is ongoing (NCT03807245).",
            "startOffset": 18188,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 23986,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Another important difference relates to the fact that adaptive immunity in babies is not expected to play a role in early life protection against GBS, as protection would be passively derived only from acquisition of maternal antibodies.",
            "startOffset": 23749,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 42856,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "The characterization of antibody persistence over time up to the end of the at-risk period may also contribute to assess the relationship between antibody levels and disease risk, especially for late-onset disease.",
            "startOffset": 42642,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 38145,
            "parents": [],
            "secId": "s0055",
            "sentence": "Based on this analysis framework, a functional antibody assay would seem preferable as a scientifically justifiable substitute endpoint to just a quantitative, non-functional antigen-binding assay.",
            "startOffset": 37948,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 38580,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0060",
            "sentence": "The safety evaluation of a candidate vaccine needs to be at least as rigorous as that required for vaccines licensed by traditional clinical development pathways.",
            "startOffset": 38418,
            "title": "Safety"
        },
        {
            "endOffset": 44680,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "Exploratory evaluations can contribute to characterize the role of phenotypic and genotypic differences in the pathogen with protection, thereby producing valuable knowledge to inform vaccine development pathways and decision-making.",
            "startOffset": 44447,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 21071,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "The considerations presented here were informed by a consensus-generating consultation process that started with a meeting of experts and specific stakeholders, organized by WHO in London on Dec 16th, 2017, and further iterative exchanges with experts and stakeholders in the field.",
            "startOffset": 20789,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 33146,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "Controls will be selected from both GBS-colonized and GBS non-colonized women matched on gestation and gender, aiming for at least 3 controls for every case.",
            "startOffset": 32989,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 15742,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Two large pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are building on their experience in polysaccharide-protein conjugation technology to develop GBS vaccines.",
            "startOffset": 15566,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 18187,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Minervax has completed a phase 1 trial in non-pregnant women 18\u201340 years of age (NCT02459262) but results have not been published to date.",
            "startOffset": 18049,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 35394,
            "parents": [],
            "refoffsets": {
                "b0230": {
                    "endOffset": 35393,
                    "startOffset": 35389
                }
            },
            "secId": "s0055",
            "sentence": "The Prentice criteria have been proposed to assess the validity of proposed substitute endpoints [46].",
            "startOffset": 35292,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 50446,
            "parents": [],
            "secId": "s0095",
            "sentence": "Multiple stakeholders should be engaged early to promote strategic alignment and agree prospectively on methodological preferences, data package requirements and success criteria, tackling priority activities outlined in Table 2.",
            "startOffset": 50217,
            "title": "Conclusions"
        },
        {
            "endOffset": 34422,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "refoffsets": {
                "b0225": {
                    "endOffset": 34421,
                    "startOffset": 34417
                }
            },
            "secId": "s0050",
            "sentence": "Maternal vaccination in non-human primate models has been shown to induce high maternal antibodies and results in transfer of functional antibodies to offspring [45].",
            "startOffset": 34256,
            "title": "Animal models"
        },
        {
            "endOffset": 40383,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "refoffsets": {
                "b0240": {
                    "endOffset": 40382,
                    "startOffset": 40378
                }
            },
            "secId": "s0065",
            "sentence": "The role of GBS maternal or neonatal colonization as a potential substitute endpoint has been discussed elsewhere and is outside the scope of this report [48].",
            "startOffset": 40224,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 34594,
            "parents": [],
            "secId": "s0055",
            "sentence": "Upon demonstration that a traditional clinical development pathway is unfeasible at a reasonable cost, alternative approaches should be considered.",
            "startOffset": 34447,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 24272,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 24271,
                    "startOffset": 24267
                }
            },
            "secId": "s0030",
            "sentence": "As early as 1933, epidemiological studies of Haemophilus influenzae type b (Hib) infections showed that serum bactericidal activity (SBA) increased with age [17].",
            "startOffset": 24110,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 26699,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "More recently, a non-capsular, outer membrane protein (OMP)-based meningococcal group B vaccine was licensed, based on indirect evidence of efficacy.",
            "startOffset": 26550,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 32562,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "The study aims to enrol approximately 500 cases and 3000 controls (Stephanie Schrag, personal communication).",
            "startOffset": 32453,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 37165,
            "parents": [],
            "secId": "s0055",
            "sentence": "Strength of association (to be determined in sero-epidemiological studies); 3.",
            "startOffset": 37087,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 29227,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 29226,
                    "startOffset": 29222
                }
            },
            "secId": "s0030",
            "sentence": "Protective levels associated with protection against acute otitis media may be higher [29].",
            "startOffset": 29136,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 31563,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "The study aims to be powered for a case-control evaluation of sero-correlates of protection for serotype Ia and III, the most common serotypes causing invasive disease in South Africa.",
            "startOffset": 31379,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 36874,
            "parents": [],
            "secId": "s0055",
            "sentence": "Assessing this requires an understanding of the underlying biological mechanism, and a causality assessment of the link between the substitute endpoint and the clinical endpoint of ultimate interest.",
            "startOffset": 36675,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 49463,
            "parents": [],
            "secId": "s0095",
            "sentence": "There is an urgent need for new tools to prevent the morbidity and mortality associated with GBS disease, and GBS vaccine development is a leading priority for protection of early life.",
            "startOffset": 49278,
            "title": "Conclusions"
        },
        {
            "endOffset": 13654,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "There is also a significant, unquantified burden of GBS-related prematurity, neurodevelopmental impairment and maternal deaths.",
            "startOffset": 13527,
            "title": "Burden"
        },
        {
            "endOffset": 50664,
            "parents": [],
            "secId": "s0095",
            "sentence": "Sources of geographical heterogeneities should be considered.",
            "startOffset": 50603,
            "title": "Conclusions"
        },
        {
            "endOffset": 25915,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Quadrivalent formulations, including serogroups W and Y in addition to A and C, were marketed internationally with no direct evidence of efficacy for the W and Y serotypes.",
            "startOffset": 25743,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 40695,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0065",
            "sentence": "In the context of a sero-epidemiological study to define serological correlates of protection, detection of maternal recto-vaginal colonization and neonatal colonization and bacterial typing is encouraged, as a secondary stratified analysis considering colonization status may contribute to data interpretation.",
            "startOffset": 40384,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 13315,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "According to recent global disease burden estimates, GBS causes 319,000 cases of early life invasive bacterial disease and 90,000 infant deaths annually.",
            "startOffset": 13162,
            "title": "Burden"
        },
        {
            "endOffset": 37948,
            "parents": [],
            "secId": "s0055",
            "sentence": "Analogy (supported by other maternal immunization platforms and by other vaccines targeting encapsulated bacteria).",
            "startOffset": 37833,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 27905,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 27904,
                    "startOffset": 27900
                }
            },
            "secId": "s0030",
            "sentence": "As a requirement, post-marketing confirmatory effectiveness studies were to be conducted, including investigating herd protection and evaluating the impact of vaccination on strain variation and carriage [25].",
            "startOffset": 27696,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 46112,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "A way to mitigate this concern would be to build a strong data package indicative of the direct protective role of the substitute immune endpoint effector (i.e., ideally establishing that the immune response is both necessary and sufficient for protection), or of the close association between the measured endpoint and the causal mediator of protection.",
            "startOffset": 45758,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 23748,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Relative to other diseases with extended time-at-risk, the time window of susceptibility to invasive GBS disease in babies is narrow, which should allow a more specific evaluation of the relationship between antibody threshold and protection over time.",
            "startOffset": 23496,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 35453,
            "parents": [],
            "secId": "s0055",
            "sentence": "The first requirement is that vaccination affects outcome.",
            "startOffset": 35395,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 16991,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "GSK is back to preclinical, reformulating the candidate vaccine, while Pfizer is developing a hexavalent formulation (Ia, Ib, II, III, IV, V).",
            "startOffset": 16849,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 46726,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0085",
            "sentence": "Even if it were possible to conduct a large randomized controlled trial testing the efficacy of a multivalent polysaccharide-protein conjugate candidate vaccine, such a trial may generate an overall vaccine efficacy estimate, and possibly serotype-specific efficacy estimates for the most frequent serotypes.",
            "startOffset": 46418,
            "title": "Rare serotypes"
        },
        {
            "endOffset": 17575,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "This vaccine development programme will aim for the development of a low-cost conjugate GBS vaccine against serotypes causing >90% of invasive GBS disease in Africa.",
            "startOffset": 17410,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 24473,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 24472,
                    "startOffset": 24468
                }
            },
            "secId": "s0030",
            "sentence": "SBA was later found to be correlated with the level of IgG antibody against the organism\u2019s CPS, allowing serum ELISA concentrations to be considered as a useful marker associated with protection [18].",
            "startOffset": 24273,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 49266,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0090",
            "sentence": "Early planning and upfront identification of financing mechanisms for pilot implementation and post-licensure evidence generation should be identified, to avoid unnecessary delays in access to life-saving interventions in the populations most in need.",
            "startOffset": 49015,
            "title": "Post licensure requirements"
        },
        {
            "endOffset": 16346,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0025": {
                    "endOffset": 16345,
                    "startOffset": 16342
                }
            },
            "secId": "s0015",
            "sentence": "Novartis, which has been acquired by GSK, developed a trivalent conjugate vaccine (Ia, Ib, III), which showed favourable safety and immunogenicity in phase I and II studies in non-pregnant and pregnant women [5].",
            "startOffset": 16134,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 13784,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0005": {
                    "endOffset": 13783,
                    "startOffset": 13780
                }
            },
            "secId": "s0010",
            "sentence": "The African continent accounts for an estimated 54% of cases of GBS invasive disease and 65% of all foetal/infant GBS deaths [1].",
            "startOffset": 13655,
            "title": "Burden"
        },
        {
            "endOffset": 25582,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 25581,
                    "startOffset": 25577
                }
            },
            "secId": "s0030",
            "sentence": "Epidemiological studies in the 1960\u2032s similarly showed an association between age and anti-capsular groups A, B and C meningococcus serum complement-dependent bactericidal assay (SBA), and between the latter and the risk of meningitis [21].",
            "startOffset": 25342,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 21744,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "Accordingly, in terms of nomenclature, we here refer to a substitute endpoint as a non-clinical pivotal endpoint which may be used to support licensing decisions, and to immune correlates of protection as immune markers shown to correlate statistically with a reduced risk of disease.",
            "startOffset": 21460,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 20788,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "Related, priority activities to are outlined in Table 2.",
            "startOffset": 20732,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 25742,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Vaccine efficacy trials leading to licensure and introduction of polysaccharide meningococcal A and A/C vaccines enabled correlate of protection to be defined.",
            "startOffset": 25583,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 22215,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 22190,
                    "startOffset": 22183
                },
                "b0080": {
                    "endOffset": 22190,
                    "startOffset": 22183
                }
            },
            "secId": "s0030",
            "sentence": "Correlates of protection have played an important role in supporting the licensure of several conjugated vaccines targeting encapsulated bacteria [15,16], as reviewed in Panel 2.",
            "startOffset": 22037,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 24110,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Learning from history: The role of correlates of protection on the development pathway of selected available vaccines",
            "startOffset": 23993,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 44287,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "The number, intensity and duration of prior GBS infections, comorbidities, the microbiome, host genetics, or pathogen characteristics may impact the type of immune response generated after natural infection as compared to a response to vaccination, with potential consequences on antibody transfer.",
            "startOffset": 43989,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 19283,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "In a trial, ethical considerations would require implementation of national and non GBS-specific WHO recommendations for infection prevention and strengthening of access to pre- and peri-natal care, ensuring appropriate medical oversight of delivery and prescription of intrapartum antibiotics in the presence of infectious risk factors, which would reduce baseline attack rates.",
            "startOffset": 18904,
            "title": "Randomized controlled vaccine clinical efficacy trial: a sample size challenge"
        },
        {
            "endOffset": 49014,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "refoffsets": {
                "b0255": {
                    "endOffset": 49013,
                    "startOffset": 49006
                },
                "b0260": {
                    "endOffset": 49013,
                    "startOffset": 49006
                }
            },
            "secId": "s0090",
            "sentence": "They may be linked to evaluations of vaccine programme implementation feasibility, as these are increasingly seen as necessary on the pathway to vaccine availability, especially in resource-limiting settings with frail health systems, where deployment of new interventions is most challenging, and where competition for scarce resources is most prevalent [51,52].",
            "startOffset": 48651,
            "title": "Post licensure requirements"
        },
        {
            "endOffset": 45496,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "A concern, regarding the validity of extrapolating a threshold indicative of antibody-mediated immunity resulting from natural exposure to post vaccination levels, relates to the possibility that other protective immune mediators, activated by natural exposure (ie antibodies targeting other antigens), are transferred to the foetus, but may not be induced by vaccination.",
            "startOffset": 45124,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 43021,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "In vaccine studies, antibody levels at birth should be evaluated as a function of timing of maternal immunization during pregnancy, for vaccination program planning.",
            "startOffset": 42856,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 15015,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "A summary of the GBS vaccine development landscape is presented in Panel 1.",
            "startOffset": 14940,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 37832,
            "parents": [],
            "secId": "s0055",
            "sentence": "Experimental reversibility (upon waning of immunity acquired post exposure); 9.",
            "startOffset": 37753,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 17700,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Minervax, in contrast, is developing a protein-based GBS vaccine, targeting the N-terminal domains of the Alp-protein family.",
            "startOffset": 17575,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 43622,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "The respective advantages and limitations of various statistical analysis methodologies should be considered.",
            "startOffset": 43513,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 35649,
            "parents": [],
            "secId": "s0055",
            "sentence": "The proposed accelerated approval pathway assumes that this can only be inferred indirectly and cannot be demonstrated pre-licensure and should be demonstrated after initial vaccine introduction.",
            "startOffset": 35454,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 20542,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "If a pre-licensure pivotal randomized controlled clinical efficacy trial is not possible, on grounds of cost or feasibility, alternative strategies to support licensure need to be considered.",
            "startOffset": 20351,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 13161,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "Group B Streptococcus (GBS) is a leading cause of maternal, foetal, neonatal and young infant invasive bacterial disease.",
            "startOffset": 13040,
            "title": "Burden"
        },
        {
            "endOffset": 32452,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "Remainders of the newborn screening dried blood spot (DBS) samples will be used for antibody measurements.",
            "startOffset": 32346,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 29135,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Correlates of protection were initially established in efficacy studies of PCV against all invasive pneumococcal disease (including bacteraemia and meningitis), but true threshold might differ according to disease entities.",
            "startOffset": 28912,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 45124,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "A risk management plan should be considered if a significant proportion of vaccinated individuals are categorized as low responders, which may justify investigating a two-dose vaccine regimen, possibly including a pre-pregnancy priming dose.",
            "startOffset": 44883,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 33982,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "refoffsets": {
                "b0210": {
                    "endOffset": 33981,
                    "startOffset": 33977
                }
            },
            "secId": "s0050",
            "sentence": "Passive transfer of antibodies acquired following experimental infection has also been shown to be partially protective in rhesus monkeys [42].",
            "startOffset": 33839,
            "title": "Animal models"
        },
        {
            "endOffset": 37752,
            "parents": [],
            "secId": "s0055",
            "sentence": "Coherence (the causality assumption does not appear to conflict with current knowledge); 8.",
            "startOffset": 37661,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 24713,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 24712,
                    "startOffset": 24708
                }
            },
            "secId": "s0030",
            "sentence": "Subsequent efficacy studies of a Hib polysaccharide vaccine candidate led to the demonstration of an association between vaccine-induced antibodies and protection from natural Hib exposure, and the definition of protective thresholds [19].",
            "startOffset": 24474,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 25045,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Post-immunization with a protein conjugate Hib CPS vaccine, a peak antibody concentration of 1 \u03bcg/mL is considered as a marker of long-term protection.",
            "startOffset": 24894,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 28234,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Randomized controlled trials initially established the protective efficacy of the 7-valent pneumococcal conjugate vaccine (PCV), which allowed the derivation of serotype-specific serum antibody protective thresholds for some serotypes, but not for the less common ones.",
            "startOffset": 27965,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 21459,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 21458,
                    "startOffset": 21454
                }
            },
            "secId": "s0025",
            "sentence": "General WHO considerations on methods leading to definitions of correlates of vaccine-induced protection have been presented elsewhere [14].",
            "startOffset": 21319,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 18670,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "However, a pivotal GBS vaccine efficacy trial would require a very large sample size, as shown in Table 1.",
            "startOffset": 18564,
            "title": "Randomized controlled vaccine clinical efficacy trial: a sample size challenge"
        },
        {
            "endOffset": 36529,
            "parents": [],
            "secId": "s0055",
            "sentence": "In this situation, whereby we want to extrapolate results from immunity studies in conditions of natural exposure with immunity resulting from vaccination, this assumes that the protective mechanism is the same in both conditions (non-vaccinated previously exposed and vaccinated), or is sufficiently close.",
            "startOffset": 36222,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 14589,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "Intrapartum antibiotic prophylaxis (IAP), guided by microbiological or clinical screening strategies, has been shown to reduce the risk of early-onset GBS disease (EOD, days 0\u20136 after birth) in some high-income settings, but has shown no impact on late-onset GBS disease (LOD, days 7\u201389) and does not prevent GBS-associated stillbirths and prematurity.",
            "startOffset": 14237,
            "title": "Burden"
        },
        {
            "endOffset": 32345,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "Controls will be babies of GBS-colonized mothers identified at participating clinical centres performing routine antenatal screening for GBS colonization.",
            "startOffset": 32191,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 18903,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0015": {
                    "endOffset": 18803,
                    "startOffset": 18800
                }
            },
            "secId": "s0020",
            "sentence": "Baseline incidences of invasive GBS disease of 1\u20133 events per 1000 live births have been reported in some low-resources settings [3], but baseline incidence in a trial will depend on standards of care and subject selection criteria.",
            "startOffset": 18671,
            "title": "Randomized controlled vaccine clinical efficacy trial: a sample size challenge"
        },
        {
            "endOffset": 37327,
            "parents": [],
            "secId": "s0055",
            "sentence": "Biological gradient (as to be determined in sero-epidemiological studies); 5.",
            "startOffset": 37250,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 18563,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "The conduct of double-blind placebo-controlled randomized trials to assess vaccine efficacy against clinically relevant, pre-defined, endpoints constitutes the gold-standard approach to generate evidence for vaccine licensure and policy decisions.",
            "startOffset": 18316,
            "title": "Randomized controlled vaccine clinical efficacy trial: a sample size challenge"
        },
        {
            "endOffset": 39921,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0065",
            "sentence": "The clinical management algorithm and clinical criteria used to trigger collection of a clinical sample for GBS culture will play a critical role in identifying cases.",
            "startOffset": 39754,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 43512,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "The target effect size and a detailed analysis plan defining the primary outcome of interest and key secondary analyses should be prospectively defined.",
            "startOffset": 43360,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 14105,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 14104,
                    "startOffset": 14101
                }
            },
            "secId": "s0010",
            "sentence": "Maternal colonization in pregnancy (ranging from about 10% to 40%) has been found in women in all geographical settings evaluated [2].",
            "startOffset": 13971,
            "title": "Burden"
        },
        {
            "endOffset": 21319,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 21318,
                    "startOffset": 21311
                },
                "b0065": {
                    "endOffset": 21318,
                    "startOffset": 21311
                }
            },
            "secId": "s0025",
            "sentence": "These considerations aim to inform vaccine development strategies, complementing recent discussions in other fora, including those organized by the US Food and Drug Administration and the UK Joint Committee on Vaccination and Immunization [12,13].",
            "startOffset": 21072,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 21940,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "The term \u2018surrogate endpoint\u2019, specifically implies that the measured marker is a causal, mechanistic mediator of protection.",
            "startOffset": 21815,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 17409,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "A BMGF-funded partnership has also been announced between PATH and The Biovac Institute, a South-African government-private partnership, aimed at developing in-country manufacturing capacity.",
            "startOffset": 17218,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 23088,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "Often, the mechanism of immunity derived from natural exposure and vaccine-induced immunity is similar, and based on functional antibodies, but protective thresholds can differ according to antibody qualitative characteristics.",
            "startOffset": 22861,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 31778,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "Cases will be matched to controls for maternal colonization status with a homotypic serotype during labour, maternal age, birth weight, newborn gender and maternal HIV status (Shabir Madhi, personal communication).",
            "startOffset": 31564,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 39280,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "refoffsets": {
                "b0240": {
                    "endOffset": 39279,
                    "startOffset": 39275
                }
            },
            "secId": "s0065",
            "sentence": "WHO preferred case definitions and ascertainment methodologies are described elsewhere [48].",
            "startOffset": 39188,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 47023,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0085",
            "sentence": "Similarly, epidemiological studies in conditions of natural exposure may generate estimates of protective serological thresholds against the most frequent serotypes, but not the less common ones.",
            "startOffset": 46828,
            "title": "Rare serotypes"
        },
        {
            "endOffset": 35919,
            "parents": [],
            "secId": "s0055",
            "sentence": "This would need to be established in sero-epidemiological studies.",
            "startOffset": 35853,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 36956,
            "parents": [],
            "secId": "s0055",
            "sentence": "The Bradford-Hill criteria have been proposed to support causality assessments: 1.",
            "startOffset": 36874,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 28713,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "The aggregate threshold was used for licensure of subsequent PCV vaccines, using head-to-head immunogenicity studies for the same serotypes, and as a stand-alone reference for the additional serotypes when new capsular types were included.",
            "startOffset": 28474,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 32190,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "Cases will be identified in 2019\u20132022 from CDC\u2019s Active Bacterial Core surveillance program.",
            "startOffset": 32098,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 20300,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "This traditional clinical development pathway would constitute a potential major obstacle to progress towards availability of a much-needed vaccine.",
            "startOffset": 20152,
            "title": "Randomized controlled vaccine clinical efficacy trial: a sample size challenge"
        },
        {
            "endOffset": 22860,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "When putting into perspective past experience with other vaccines and considerations on substitute immunological endpoints for GBS, important similarities and differences can be highlighted.",
            "startOffset": 22670,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 36221,
            "parents": [],
            "secId": "s0055",
            "sentence": "The full mediation condition relates to the observation that the substitute variable is a full mediator of protection.",
            "startOffset": 36103,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 38280,
            "parents": [],
            "secId": "s0055",
            "sentence": "Alternatively, strong evidence of the correspondence between functional and non-functional quantitative assays should be demonstrated.",
            "startOffset": 38146,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 41889,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "The analysis of a maternal post-immunization serum sample may constitute a pragmatic approach to capture an overall target level that would be associated with a reduction of the overall risk of adverse outcomes, including stillbirth, maternal and infant outcomes.",
            "startOffset": 41626,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 48061,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0090",
            "sentence": "Licensure may be conditional, subject to review after the conduct of such studies.",
            "startOffset": 47979,
            "title": "Post licensure requirements"
        },
        {
            "endOffset": 44882,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "If the vaccine-induced antibody levels are far above the antibody protective threshold defined by studies in conditions of natural exposure, the likelihood that the vaccine is protective will be higher.",
            "startOffset": 44680,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 49677,
            "parents": [],
            "secId": "s0095",
            "sentence": "While randomized controlled clinical efficacy trials constitute the gold standard for evidence generation, there are significant obstacles to conducting such trials to assess efficacy against GBS invasive disease.",
            "startOffset": 49464,
            "title": "Conclusions"
        },
        {
            "endOffset": 51475,
            "parents": [],
            "secId": "s0095",
            "sentence": "Early planning of confirmatory evaluation according to agreed methodologies, with identified financing, will be key to reduce delays to wide-scale use, including in low resource settings.",
            "startOffset": 51288,
            "title": "Conclusions"
        },
        {
            "endOffset": 16712,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 16711,
                    "startOffset": 16708
                }
            },
            "secId": "s0015",
            "sentence": "Undetectable serotype-specific capsular antibodies at baseline and maternal HIV infection were, however, associated with reduced immunogenicity [7].",
            "startOffset": 16564,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 15967,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 15966,
                    "startOffset": 15963
                }
            },
            "secId": "s0015",
            "sentence": "Ten GBS capsular envelope polysaccharide (CPS)-based serotypes have been described, however, the majority of invasive disease in young infants is caused by a few of these serotypes (predominantly Ia, Ib, II, III, IV, V) [4].",
            "startOffset": 15743,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 41451,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "The choice of sampling timepoints in both mothers and offspring will be a key determinant of the evaluation of the association between antibody levels and protection.",
            "startOffset": 41285,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 31072,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "In South Africa, a prospective, observational cohort of 35,000 mother-newborn pairs was enrolled between 2015 and 2017.",
            "startOffset": 30953,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 39187,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0065",
            "sentence": "Standard case definitions and ascertainment methodologies are needed to produce clinically relevant estimates of effect for both the evaluation of vaccine efficacy against a clinical endpoint, and for the evaluation of association between antibody levels and clinical outcomes in a sero-epidemiologic study.",
            "startOffset": 38880,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 45631,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "In theory, this effect could be complete, or only partial, if the measured antibody is just one mediator of protection amongst others.",
            "startOffset": 45497,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 26218,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 26217,
                    "startOffset": 26213
                }
            },
            "secId": "s0030",
            "sentence": "Serological criteria alone without direct evidence of efficacy supported the introduction of the meningococcal C conjugate vaccine in the United Kingdom in 1999, and it was only when early post-licensure evaluation produced efficacy estimates that the licensure criteria were clinically validated [22].",
            "startOffset": 25916,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 48228,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0090",
            "sentence": "Policy makers would also likely require studies to assess effectiveness and impact before advising in favour of prioritizing resources for large-scale implementation.",
            "startOffset": 48062,
            "title": "Post licensure requirements"
        },
        {
            "endOffset": 40224,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0065",
            "sentence": "Highest standards of sterile technique in sample collection should be applied, to avoid sample bacterial contamination and maximize sensitivity, which is drastically reduced if an insufficient blood volume is collected.",
            "startOffset": 40005,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 34255,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "refoffsets": {
                "b0185": {
                    "endOffset": 34254,
                    "startOffset": 34244
                },
                "b0215": {
                    "endOffset": 34254,
                    "startOffset": 34244
                },
                "b0220": {
                    "endOffset": 34254,
                    "startOffset": 34244
                }
            },
            "secId": "s0050",
            "sentence": "Animal models have also been used to study the protective effect of maternal immunisation on the offspring and have demonstrated placental antibody transfer and favourable outcomes, for both capsular envelope polysaccharide and protein-based candidate vaccines [37,43,44].",
            "startOffset": 33983,
            "title": "Animal models"
        },
        {
            "endOffset": 51287,
            "parents": [],
            "secId": "s0095",
            "sentence": "A pathway involving regulatory decision-making based on indirect evidence of clinical impact will require post-licensure confirmation of public health benefits associated with vaccine use in large populations, possibly during a pilot implementation stage.",
            "startOffset": 51032,
            "title": "Conclusions"
        },
        {
            "endOffset": 27695,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "In 2015, the MenB-FHbp and MenB-4C protein vaccines were licensed by the US FDA, based on regulations for accelerated approval, which supports approval of vaccines for serious or life-threatening diseases based on safety and indirect evidence reasonably likely to predict clinical benefit, in this case hSBA responses.",
            "startOffset": 27377,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 32988,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "In case of disease, another maternal and infant sample will be taken and antibody titres compared to those at birth.",
            "startOffset": 32872,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 43160,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "Important statistical considerations driving the prospective development of analysis plans need to be defined.",
            "startOffset": 43050,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 43359,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 43255,
                    "startOffset": 43251
                }
            },
            "secId": "s0080",
            "sentence": "WHO has expressed a preference for an 80% level of protection provided by GBS vaccination [10], and this should guide sample size determination for an approach using immune correlates of protection.",
            "startOffset": 43161,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 47769,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0090",
            "sentence": "In the absence of such evidence pre-licensure, impact estimates must rely on mathematical models prone to imperfect assumptions.",
            "startOffset": 47641,
            "title": "Post licensure requirements"
        },
        {
            "endOffset": 21814,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "Such a correlate may, or may not, be a causal mediator of protection.",
            "startOffset": 21745,
            "title": "Alternative pathway via correlates of protection"
        },
        {
            "endOffset": 14236,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "Although incidence is highest during the first days of life, the risk of GBS disease in young infants extends to 3 months of life.",
            "startOffset": 14106,
            "title": "Burden"
        },
        {
            "endOffset": 22670,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "The type of studies that have contributed to establishing evidence of correlates of protection have included sero-epidemiological studies, showing associations between antibody levels and subsequent incidence of disease, passive immunization experiments with serum transfer in animal models or humans showing protection; animal models of vaccine-induced protection; in vitro bacterial killing assays; and ultimately human efficacy, effectiveness studies.",
            "startOffset": 22216,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 45757,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "Such a situation may lead to an overestimation of the likely vaccine efficacy based on the substitute immunological endpoint.",
            "startOffset": 45632,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 50795,
            "parents": [],
            "secId": "s0095",
            "sentence": "A global strategy should be developed, and similar studies should be undertaken in high-, low- and middle-income country settings.",
            "startOffset": 50665,
            "title": "Conclusions"
        },
        {
            "endOffset": 47640,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0090",
            "sentence": "An inherent disadvantage of an approach based on a substitute endpoint relates to the imprecise characterization of the individual and public health impact of the vaccine, better estimated through direct evidence generated in a large double blind randomized controlled trial.",
            "startOffset": 47365,
            "title": "Post licensure requirements"
        },
        {
            "endOffset": 41263,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "refoffsets": {
                "b0245": {
                    "endOffset": 41262,
                    "startOffset": 41258
                }
            },
            "secId": "s0070",
            "sentence": "A collaborative initiative towards the development of validated standardized immunoassays is ongoing [49].",
            "startOffset": 41157,
            "title": "Assay quality systems"
        },
        {
            "endOffset": 40004,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0065",
            "sentence": "Criteria used to trigger sample collection should be set to maximize case capture.",
            "startOffset": 39922,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 37086,
            "parents": [],
            "secId": "s0055",
            "sentence": "Temporal sequence of association (exposure triggers appearance of antibodies, the role of which precede the clinical outcome); 2.",
            "startOffset": 36957,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 42125,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "Thresholds may also vary according to clinical outcomes considered.",
            "startOffset": 42058,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 25342,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 25341,
                    "startOffset": 25337
                }
            },
            "secId": "s0030",
            "sentence": "Higher levels of antibodies have been associated with protection against nasopharyngeal carriage [20].",
            "startOffset": 25240,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 23362,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0030",
            "sentence": "In all the non-GBS examples discussed in Panel 2, some efficacy data were part of the evidence package used for licensure, although not necessarily specific to all antigens included in the vaccine.",
            "startOffset": 23165,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 42057,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "However, sources of heterogeneity need to be considered, as the gestational age at vaccination, prematurity and co-morbidities affect placental transfer of antibodies.",
            "startOffset": 41890,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 30790,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "refoffsets": {
                "b0185": {
                    "endOffset": 30789,
                    "startOffset": 30779
                },
                "b0195": {
                    "endOffset": 30789,
                    "startOffset": 30779
                },
                "b0200": {
                    "endOffset": 30789,
                    "startOffset": 30779
                }
            },
            "secId": "s0040",
            "sentence": "An inverse association between levels of antibodies and neonatal risk of invasive disease has also been shown for some protein candidate antigens, but not others [37,39,40].",
            "startOffset": 30617,
            "title": "Current evidence base"
        },
        {
            "endOffset": 32807,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "secId": "s0045",
            "sentence": "Pilot studies are underway both in the UK and Uganda to assess the feasibility of prospectively enrolling a high number of mother-infant pairs and collect maternal and cord sera (150.000 in the UK, 35.000 in Uganda), using similar methodologies.",
            "startOffset": 32562,
            "title": "Ongoing or planned sero-epidemiology studies"
        },
        {
            "endOffset": 47978,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0090",
            "sentence": "In such a context, regulators are likely to consider sero-correlate-based indirect evidence of protection only in the context of agreed post-approval studies for further evaluation of effectiveness and impact.",
            "startOffset": 47769,
            "title": "Post licensure requirements"
        },
        {
            "endOffset": 16133,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Both companies have developed candidate vaccines targeting the major serotypes associated with neonatal disease, using the CRM197 diphtheria protein for conjugation.",
            "startOffset": 15968,
            "title": "Vaccine landscape"
        },
        {
            "endOffset": 47335,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0085",
            "sentence": "Later, subsequent post-licensure investigations may allow more detailed characterization.",
            "startOffset": 47246,
            "title": "Rare serotypes"
        },
        {
            "endOffset": 39618,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0065",
            "sentence": "The use of a composite endpoint, including different clinically relevant disease entities (e.g., GBS-confirmed stillbirth, EOD, LOD, and fatal invasive disease) may need to be considered to reduce study size requirements.",
            "startOffset": 39397,
            "title": "Endpoint case definitions"
        },
        {
            "endOffset": 41625,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0075",
            "sentence": "Several options could be considered to define the primary time-point used to assess protection thresholds.",
            "startOffset": 41519,
            "title": "Sampling timepoints"
        },
        {
            "endOffset": 34987,
            "parents": [],
            "secId": "s0055",
            "sentence": "Important consensus recommendations about the use of an immunological substitute endpoint are highlighted here, and an analysis framework for critical appraisal of evidence is presented in Panel 3.",
            "startOffset": 34790,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 35797,
            "parents": [],
            "secId": "s0055",
            "sentence": "The second criterion is that vaccination affects surrogates (in this case antibodies), which can be demonstrated in vaccine immunogenicity studies.",
            "startOffset": 35650,
            "title": "Defining the way forward"
        },
        {
            "endOffset": 50891,
            "parents": [],
            "secId": "s0095",
            "sentence": "Protective thresholds may differ according to local epidemiology and host and pathogen factors.",
            "startOffset": 50796,
            "title": "Conclusions"
        },
        {
            "endOffset": 49987,
            "parents": [],
            "secId": "s0095",
            "sentence": "Existing evidence suggest this may be a viable approach.",
            "startOffset": 49931,
            "title": "Conclusions"
        },
        {
            "endOffset": 28912,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 28911,
                    "startOffset": 28907
                }
            },
            "secId": "s0030",
            "sentence": "Post-licensure, serotype-specific protective thresholds documented from vaccine effectiveness studies showed some variation relative to the initially inferred aggregate correlate of protection [28].",
            "startOffset": 28714,
            "title": "Past experience on the role of correlates of protection on the pathway to vaccine availability"
        },
        {
            "endOffset": 43853,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0080",
            "sentence": "Geographical heterogeneities should be considered, as the protective threshold may differ according to various host and pathogen factors.",
            "startOffset": 43716,
            "title": "Statistical considerations"
        },
        {
            "endOffset": 29941,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Establishing a valid correlate of protection for the licensure of GBS vaccines: available evidence, ongoing studies"
                }
            ],
            "refoffsets": {
                "b0160": {
                    "endOffset": 29902,
                    "startOffset": 29895
                },
                "b0165": {
                    "endOffset": 29902,
                    "startOffset": 29895
                },
                "b0170": {
                    "endOffset": 29902,
                    "startOffset": 29895
                },
                "b0175": {
                    "endOffset": 29902,
                    "startOffset": 29895
                },
                "b0180": {
                    "endOffset": 29902,
                    "startOffset": 29895
                },
                "b0185": {
                    "endOffset": 29902,
                    "startOffset": 29895
                },
                "b0190": {
                    "endOffset": 29940,
                    "startOffset": 29936
                }
            },
            "secId": "s0040",
            "sentence": "A number of studies have since reported a reduced risk of invasive disease in neonates and young infants associated with higher maternal antibodies acquired following natural exposure [32\u201337], as presented in a recent review [38].",
            "startOffset": 29711,
            "title": "Current evidence base"
        },
        {
            "endOffset": 48458,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Defining the way forward"
                }
            ],
            "secId": "s0090",
            "sentence": "Post-licensure studies offer the possibility to further assess the public health impact of the vaccine, including its preventive role against less common endpoints, such as mortality or multi-factorial syndromes like prematurity.",
            "startOffset": 48229,
            "title": "Post licensure requirements"
        }
    ],
    "docId": "S0264410X19305018",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "vekemansj@who.int",
                "first": "Johan",
                "initial": "J.",
                "last": "Vekemans"
            },
            {
                "email": "jonathan.crofts@phe.gov.uk",
                "first": "Jonathan",
                "initial": "J.",
                "last": "Crofts"
            },
            {
                "email": null,
                "first": "Carol J.",
                "initial": "C.J.",
                "last": "Baker"
            },
            {
                "email": "d.goldblatt@ucl.ac.uk",
                "first": "David",
                "initial": "D.",
                "last": "Goldblatt"
            },
            {
                "email": "pheath@sgul.ac.uk",
                "first": "Paul T.",
                "initial": "P.T.",
                "last": "Heath"
            },
            {
                "email": "madhis@rmpru.co.za",
                "first": "Shabir A.",
                "initial": "S.A.",
                "last": "Madhi"
            },
            {
                "email": "kiledoar@sgul.ac.uk",
                "first": "Kirsty",
                "initial": "K.",
                "last": "Le Doare"
            },
            {
                "email": "nick.andrews@phe.gov.uk",
                "first": "Nick",
                "initial": "N.",
                "last": "Andrews"
            },
            {
                "email": "andrew.pollard@paediatrics.ox.ac.uk",
                "first": "Andrew J.",
                "initial": "A.J.",
                "last": "Pollard"
            },
            {
                "email": null,
                "first": "Samir K.",
                "initial": "S.K.",
                "last": "Saha"
            },
            {
                "email": "zha6@cdc.gov",
                "first": "Stephanie J.",
                "initial": "S.J.",
                "last": "Schrag"
            },
            {
                "email": "p.smith@lshtm.ac.uk",
                "first": "Peter G.",
                "initial": "P.G.",
                "last": "Smith"
            },
            {
                "email": "dkaslow@path.org",
                "first": "David C.",
                "initial": "D.C.",
                "last": "Kaslow"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.04.039",
        "firstpage": "3190",
        "issn": "0264410X",
        "keywords": [
            "Correlates of protection",
            "Group B Streptococcus",
            "Maternal immunization",
            "Neonatal sepsis",
            "Vaccines"
        ],
        "lastpage": "3198",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations"
    }
}